The Application of Single-Cell Technologies and Mass Cytometry (CyTOF) in Tumor Microenvironments (TMEs), Cancer Diagnosis, and Drug Discovery

Dear Colleagues,

Although there has been continuous improvement in the survival and related outcomes of patients with cancer over time, cancer patients still suffer from high mortality rates. Moreover, thus far scientists have striven to develop a novel therapy based on the characteristics of numerous cancers. For instance, recent research revealed elevated immune system activity through immune checkpoint-related therapy as a novel targeted therapeutic strategy to cure cancers. Furthermore, recent studies have indicated the distinct features and heterogeneity of tumors through high-throughput sequencing and mass spectrometry (MS) analysis. Therefore, it is critical to identify novel targets for cancer therapeutics and develop personalized medicine that can be used in the treatment of cancer patients. Moreover, aiming to treat molecular and cellular variability under different individual cancer patients is a new direction for cancer research. Single-cell RNA sequencing (scRNA-seq) and ass cytometry (CyTOF) allow researchers to investigate the cell-type composition of primary tumor resection specimens, minimizing technical barriers that have previously impeded our perspective on intra-tumor heterogeneity. Additionally, single-cell technologies have been widely utilized to decipher the diversity within tumors and explore the intricate nature of the tumor microenvironment (TME), as well as cancer diagnosis and drug discovery. This Special Issue of Cancers, entitled “The Application of Single-Cell Technologies and Mass Cytometry (CyTOF) in Tumor Microenvironment (TME), Cancer Diagnosis, and Drug Discovery”, seeks papers on the following topics: data mining; bioinformatics; drug discovery; novel biomarkers; cancer diagnosis; single-cell technologies; mass cytometry (CyTOF); and tumor microenvironment (TME).

Dr. Meng-Chi Yen
Dr. Chih-Yang Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• data mining
• bioinformatics
• drug discovery
• novel biomarkers
• cancer diagnosis
• single-cell technologies
• mass cytometry (CyTOF)
• tumor microenvironment (TME)